Published Research & Science Studies
Review the peer-reviewed publications and research papers examining the scientific foundation of the NAP™ and bio-frequency technologies utilized in the NeuroRester system.
Nature and Science of Sleep Study [Pavlova et al., 2019]
Aims: This study evaluated the physiological effects of the underlying bio-frequency technology on sleep metrics.
Findings: The study observed a correlation between bio-frequency protocols and improvements in sleep quality scores—with users in that study reporting, on average, meaningfully better sleep. Individual results will vary.
Mayo Clinic Circulation & Vascular Function Study [Stewart et al., 2020]
Aims: This double-blind, randomized study examined the physiological impacts of the underlying bio-frequency technology on microvascular circulation and endothelial function.
Findings: Researchers observed improvements in circulatory markers, specifically endothelial vascular function and microvascular blood flow, in study participants. The NAP™ technology applies these non-pharmacological principles to everyday circulation wellness support. Individual results will vary.
Note: Study funded by Biomobie Regenerative Medicine; authors reported no personal financial interests in the research.
Mayo Clinic Nitric Oxide & Blood Pressure Study [Kim et al., 2020]
Aims: This 12-week double-blind, randomized study evaluated the effects of the underlying bio-frequency technology on blood pressure regulation and plasma nitric oxide levels in subjects with metabolic syndrome.
Findings: The study observed a significant increase in circulating plasma nitric oxide levels in the active therapy group. Additionally, significant blood pressure reductions were observed in subjects with resting hypertension compared to the sham group, alongside lowered peak systolic blood pressure during exercise. Individual results will vary.
Note: Study funded by Biomobie Regenerative Medicine; authors reported no personal financial interests in the research.
Regulatory References & Disclaimers
References & Disclaimers
References:
[1] Kim CH et al. Blood Pressure, 2019. DOI: 10.1080/08037051.2019.1649591
[2] Stewart GM et al. J Clin Hypertens, 2020. DOI: 10.1111/jch.13877
(Mayo Clinic study funded by Biomobie Regenerative Medicine, Shanghai, China; authors reported no personal financial interests in the research.)
About NeuroRester Corp. R&D by Biomobie, with studies conducted at Mayo Clinic, NeuroRester is the pioneer of the Wellness 2.0 era. We own the exclusive BioBoosti™ and NAP™ technologies, dedicated to supporting human physiological wellness through non-invasive means.
Disclaimer: NeuroRester is a premium health and wellness lifestyle device. It is not a medical device and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. The statements in this document have not been evaluated by the Food and Drug Administration. NeuroRester should not be used as a substitute for professional medical advice, diagnosis, or treatment. If you have a medical condition or are taking medication, consult a qualified healthcare provider before use. Individual results will vary.